Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

BioNTech SE

Pfizer

There are two key reasons why vaccine stocks won't get a boost from mandates.

Why Vaccine Mandates Won't Drive Pfizer, BioNTech, and Moderna Stocks Higher

And they might result in near-term and long-term share gains.

5 Reasons Moderna May Prove Wall Street Wrong

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna announces submission of data to European Medicines Agency for its COVID-19 vaccine booster.

Moderna Announces Submission of Data to European Medicines Agency for its COVID-19 Vaccine Booster

AMC Entertainment

Alibaba

Clover Health Investments

GameStop

Robinhood

Microvast Holdings

Palantir Technologies

Tesla

Wish

One of the defining characteristics of a meme stock is how much discussion it generates on social media, particularly on r/WallStreetBets and other Reddit groups focused on single stocks.

How the 10 Most Buzzworthy Meme Stocks Performed in August

If so, we might live through 2020 all over again.

This Could Mean Moderna and BioNTech Are Actually Dirt Cheap

Jazz Pharmaceuticals

Zogenix

These fast-paced companies should generate jaw-dropping revenue growth over the next three years.

3 Hypergrowth Stocks Expected to Increase Sales 1,185% to 12,629% by 2023

Boosters should deliver good news in the near term and the long term.

Here's What the U.S. Booster Plan Means for Pfizer and Moderna

The company is clearly determined to win regulatory authorization for its coronavirus vaccine booster.

Why Moderna Trounced the Market on Thursday

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna to present at upcoming investor conferences in September 2021.

Moderna to Present at Upcoming Investor Conferences in September 2021

Regeneron Pharmaceuticals

Vertex Pharmaceuticals

REGN, MRNA & VRTX are the three biotech companies that are likely to outperform the sector on the back of strong fundamentals.

3 Large Biotech Stocks Worth Adding to Your Portfolio

Moderna's (MRNA) booster dose of COVID-19 vaccine elicits antibody levels that were much higher than that seen after the two-dose primary schedule.

Moderna (MRNA) Gives First COVID Jab Booster Data to the FDA

Charles River Laboratories

Devon Energy

Fortinet

Gartner

Marathon Oil

Nucor

Shares of vaccine-maker Moderna have skyrocketed more than 270% this year.

These Top Stocks Are Leading The S&P 500 To New Highs In 2021

Microsoft

Netflix

Starbucks

Wells Fargo

Q.ai runs daily factor models to get the most up-to-date reading on stocks and ETFs. Today, our deep-learning algorithms have identified Netflix among others.

Netflix Ranked Among Today's Trending Stocks As We Kick Off September Trading Month

There's more good news on the way for these two coronavirus vaccine developers.

These 2 Unstoppable Stocks Just Got a Shot in the Arm

Novavax

Although a recent controversy with competitor MRNA might lift NVAX stock in the near term, it's not something to depend on. The post Moderna Japan Scare Might Offer a Small Lift to Still-Alive Novavax Stock appeared first on InvestorPlace.

Moderna Japan Scare Might Offer a Small Lift to Still-Alive Novavax Stock

Moderna Inc (NASDAQ: MRNA) is pushing ahead for authorization of a third shot of its COVID-19 vaccine as a booster. What Happened: The Massachusetts-based company said in a statement Wednesday that it had initiated its submission to the U.S. Food and Drug Administration for evaluation of a booster dose of its vaccine at the 50 microgram dose level.

Moderna Seeks FDA Approval For COVID-19 Booster Shot

Moderna Inc. MRNA, +3.52% said late Wednesday it is submitting documents to the U.S. Food and Drug Administration (FDA) for the evaluation of a booster dose of its COVID-19 vaccine as a 50-microgram dose. The biotech company said it expects to submit data to European authorities and others around the world in the coming days.

Moderna asks FDA to evaluate COVID-19 vaccine booster candidate

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna announces submission of initial data to U.S. FDA for its COVID-19 vaccine booster.

Moderna Announces Submission of Initial Data to U.S. FDA for Its COVID-19 Vaccine Booster

DexCom

U.S. indices had a mixed day of trading Wednesday as investors weigh rising COVID-19 Delta variant cases nationwide. The Invesco QQQ Trust Series 1 (NASDAQ: QQQ) gained 0.17% to $380.58

Moderna And DexCom Lead The Nasdaq-100

The reasons to get vaccinated keep piling up.

Why Shares of Moderna Are Up Today

Pfizer and Moderna have experienced tremendous success with their COVID-19 vaccines recently, which have swelled their coffers. Despite that, the Street is projecting a decline in revenue for both companies in the next few years.

Pfizer Vs. Moderna Stock: Which Is The Better Buy?

Moderna, Inc. (NASDAQ: MRNA) found itself in a controversy after Japan suspended the use of about 2.6 million doses of the company's COVID-19 vaccine following reports of contamination. Three lots of Moderna's COVID-19 vaccine — lot numbers 3004667, 3004734 and 3004956 — were suspended following reports from vaccination sites of a potential foreign particulate substance observed in unused vials from lot 3004667.

Moderna Reviews Contamination In Vaccine Lot Distributed In Japan

Let's look to rival Pfizer for some clues.

How Close Is the Moderna Vaccine to Approval? (And What Does That Mean for the Stock?

According to a study in Belgium, Moderna Inc's (NASDAQ: MRNA) COVID-19 vaccine generated more than double the antibodies than the shot made by Pfizer Inc (NYSE: PFE) - BioNTech SE (NASDAQ: BNTX).  The research study assessed almost 2,500 workers at a major Belgium hospital system, directly comparing immune responses.

Moderna's COVID-19 Shot Elicits Higher Antibodies Than Pfizer/BioNTech Jab, Study Suggests

Japan allows use of uncontaminated vials from the same lots of Moderna's (MRNA) COVID-19 vaccine that had some contaminated vials, which led to the temporary halt of vaccination in some parts of the country.

News for Moderna Stock (MRNA)